4.7 Article

Comparison of migration disturbance potency of epigallocatechin gallate (EGCG) synthetic analogs and EGCG PEGylated PLGA nanoparticles in rat neurospheres

期刊

FOOD AND CHEMICAL TOXICOLOGY
卷 123, 期 -, 页码 195-204

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.fct.2018.10.055

关键词

Food supplements; Neural progenitor cells; Migration; Neurospheres; Developmental neurotoxicity

资金

  1. University of Girona [MPCUdG2016/036]
  2. Catalonian government [2017SGR00385]
  3. Spanish grants from Fundacion Ramon Areces
  4. Institute de Salud Carlos III [PI1400329]
  5. Erasmus + EU Programme
  6. Generalitat de Catalunya [CVE-DOGC-B-14206020-2014]

向作者/读者索取更多资源

Epigallocatechin gallate (EGCG), the main catechin of green tea, is described to have potential health benefits in several fields like oncology, neurology or cardiology. Currently, it is also under pre-clinical investigation as a potential therapeutic or preventive treatment during pregnancy against developmental adverse effects induced by toxic substances. However, the safety of EGCG during pregnancy is unclear due to its proven adverse effects on neural progenitor cells' (NPCs) migration. As lately several strategies have arisen to generate new therapeutic agents derived from EGCG, we have used the rat 'Neurosphere Assay' to characterize and compare the effects of EGCG structurally related compounds and EGCG PEGylated PLGA nanoparticles on a neurodevelopmental key event: NPCs migration. Compounds structurally-related to EGCG induce the same pattern of NPCs migration alterations (decreased migration distance, decreased formation of migration corona, chaotic orientation of cellular processes and decreased migration of neurons at higher concentrations). The potency of the compounds does not depend on the number of galloyl groups, and small structure variations can imply large potency differences. Due to their lower toxicity observed in vitro in NPCs, 4,4'-bis[(3,4,5-trihydroxybenzoyl)oxy]-1,1'-biphenyl and EGCG PEGylated PLGA nanoparticles are suggested as potential future therapeutic or preventive alternatives to EGCG during prenatal period.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

Adelina Orellana, Pablo Garcia-Gonzalez, Sergi Valero, Laura Montrreal, Itziar de Rojas, Isabel Hernandez, Maitee Rosende-Roca, Liliana Vargas, Juan Pablo Tartari, Ester Esteban-De Antonio, Urszula Bojaryn, Leire Narvaiza, Emilio Alarcon-Martin, Montserrat Alegret, Daniel Alcolea, Alberto Lleo, Lluis Tarraga, Vanesa Pytel, Amanda Cano, Marta Marquie, Merce Boada, Agustin Ruiz

Summary: This study established internal cutoffs for CSF biomarkers to differentiate between Alzheimer's disease patients and amyloid-negative subjective cognitive decline individuals. The results obtained by two different methods showed good agreement but are not interchangeable. CLEIA is a good and faster alternative for providing AT(N) classification. AT(N) classifiers increase the certainty of mild cognitive impairment prognosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Pharmacology & Pharmacy

Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations

Triana Espinosa-Jimenez, Oriol Busquets, Amanda Cano, Elena Sanchez-Lopez, Ester Verdaguer, Antoni Parcerisas, Jordi Olloquequi, Carme Auladell, Jaume Folch, Walter Wahli, Manuel Vazquez-Carrera, Antoni Camins, Miren Ettcheto

Summary: Peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) plays a key role in microglial homeostasis and metabolism in the central nervous system. However, its contribution to neuronal and memory processes is still not well-understood. This study aimed to evaluate the role of PPAR beta/delta in neuropathological pathways associated with memory impairment and the modulation of these pathways by obesity. The results showed that PPAR beta/delta deficiency affects neuronal and synaptic structure, leading to memory dysfunction.

FRONTIERS IN PHARMACOLOGY (2022)

Review Medicine, Research & Experimental

Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders

Jordi Olloquequi, Amanda Cano, Elena Sanchez-Lopez, Marina Carrasco, Ester Verdaguer, Ana Fortuna, Jaume Folch, Monica Bullo, Carme Auladell, Antoni Camins, Miren Ettcheto

Summary: PTP1B is a potential target for the treatment of neurological diseases, as its activation in brain cells can lead to various neuronal deficits. However, inhibition of PTP1B has shown promising therapeutic effects and potential to improve cognitive processes. Clinical trials evaluating the neurological benefits of PTP1B inhibition are still needed.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Article Biochemistry & Molecular Biology

Extracellular vesicles, the emerging mirrors of brain physiopathology

Amanda Cano, Miren Ettcheto, Mireia Bernuz, Raquel Puerta, Ester Esteban de Antonio, Elena Sanchez-Lopez, Eliana B. Souto, Antonio Camins, Merce Marti, Maria Isabel Pividori, Merce Boada, Agustin Ruiz

Summary: Extracellular vesicles are secreted by cells and play important roles in intercellular communication, immune responses, human reproduction, and synaptic plasticity. They have potential as biomarkers for diseases due to their biological relevance and easy accessibility. They can also be used as mirrors of brain diseases as they can cross the blood-brain barrier. This review explores their biogenesis, functions, and potential in clinical practice, as well as their role in major human brain diseases.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2023)

Article Biochemistry & Molecular Biology

The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment

Marta Marquie, Fernando Garcia-Gutierrez, Adelina Orellana, Laura Montrreal, Itziar de Rojas, Pablo Garcia-Gonzalez, Raquel Puerta, Claudia Olive, Amanda Cano, Isabel Hernandez, Maitee Rosende-Roca, Liliana Vargas, Juan Pablo Tartari, Ester Esteban-De Antonio, Urszula Bojaryn, Mario Ricciardi, Diana M. Ariton, Vanesa Pytel, Montserrat Alegret, Gemma Ortega, Ana Espinosa, Alba Perez-Cordon, Angela Sanabria, Nathalia Munoz, Nuria Lleonart, Nuria Aguilera, Ainhoa Garcia-Sanchez, Emilio Alarcon-Martin, Lluis Tarraga, Agustin Ruiz, Merce Boada, Sergi Valero

Summary: This study found that the association between Alzheimer's disease biomarkers and neuropsychiatric symptoms has a significant impact on the conversion to dementia in patients with mild cognitive impairment. A total of 500 individuals with MCI were followed-up yearly, and it was found that certain AT(N) profiles and the presence of depression and apathy were associated with a higher risk of conversion. The additive combination of AT(N) profile with depression exacerbates the risk of conversion, and a synergic effect of prodromal AD profile with depressive symptoms is evidenced.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Mendelian Randomisation Confirms the Role of Y-Chromosome Loss in Alzheimer's Disease Aetiopathogenesis in Men

Pablo Garcia-Gonzalez, Itziar de Rojas, Sonia Moreno-Grau, Laura Montrreal, Raquel Puerta, Emilio Alarcon-Martin, Ines Quintela, Adela Orellana, Victor Andrade, Pamela V. Martino Adami, Stefanie Heilmann-Heimbach, Pilar Gomez-Garre, Maria Teresa Perinan, Ignacio Alvarez, Monica Diez-Fairen, Raul Nunez Llaves, Claudia Olive Roig, Guillermo Garcia-Ribas, Manuel Menendez-Gonzalez, Carmen Martinez, Miquel Aguilar, Mariateresa Buongiorno, Emilio Franco-Macias, Maria Eugenia Saez, Amanda Cano, Maria J. Bullido, Luis Miguel Real, Eloy Rodriguez-Rodriguez, Jose Luis Royo, Victoria Alvarez, Pau Pastor, Gerard Pinol-Ripoll, Pablo Mir, Miguel Calero Lara, Miguel Medina Padilla, Pascual Sanchez-Juan, Angel Carracedo, Sergi Valero, Isabel Hernandez, Lluis Tarraga, Alfredo Ramirez, Merce Boada, Agustin Ruiz

Summary: Mosaic loss of chromosome Y (mLOY) is a common somatic event associated with Alzheimer's disease (AD) and can be age-confounded in genome-wide association studies. This study used Mendelian randomisation to construct an age-independent mLOY polygenic risk score (mloy-PRS) and found that higher genetic risk for mLOY was associated with faster progression to AD in men with mild cognitive impairment. The study suggests that mLOY is involved in AD pathogenesis and shows associations with cerebrospinal fluid biomarkers.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Correlations between the NMR Lipoprotein Profile, APOE Genotype, and Cholesterol Efflux Capacity of Fasting Plasma from Cognitively Healthy Elderly Adults

Itziar de Rojas, Laura del Barrio, Isabel Hernandez, Laura Montrreal, Pablo Garcia-Gonzalez, Marta Marquie, Sergi Valero, Amanda Cano, Adelina Orellana, Merce Boada, Santos Manes, Agustin Ruiz

Summary: Cholesterol efflux capacity (CEC), which is closely related to Alzheimer's disease and other clinical conditions, is determined by APOE genotype and plasma metabolome profile. In this study, it was found that plasma 3-hydroxybutyrate and male sex were strongly correlated with CEC. Most NMR particles associated with CEC were not correlated with APOE genotype. The study confirmed the impact of APOE genotype on plasma lipoprotein particles and omega-3 fatty acids independently of plasma cholesterol level.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Chemistry, Multidisciplinary

2(1H)-Pyrazinones from acyclic building blocks: methods of synthesis and further derivatizations

Gerard Riesco-Llach, Marta Planas, Lidia Feliu, John A. Joule

Summary: Pyrazinones are components of natural substances and are important for the synthesis of bioactive molecules. This review summarizes the strategies developed for the synthesis of pyrazinones from acyclic precursors, particularly alpha-amino acid-derived units, from the earliest examples in 1905 to the latest research in 2021.

RSC ADVANCES (2023)

Review Pharmacology & Pharmacy

Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges

Amanda Cano, Alvaro Munoz-Morales, Elena Sanchez-Lopez, Miren Ettcheto, Eliana B. Souto, Antonio Camins, Merce Boada, Agustin Ruiz

Summary: Neurodegenerative diseases have unknown etiology in many cases and lack effective treatments. The blood-brain barrier poses a challenge for drug delivery. Exosomes, secreted vesicles, have emerged as promising therapeutic tools due to their natural origin and molecular similarities. They are particularly promising for targeting neurodegenerative diseases due to the difficulty of accessing the brain and the complexity of the diseases.

PHARMACEUTICS (2023)

Article Multidisciplinary Sciences

A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress

Xavier Morato, Marta Marquie, Juan Pablo Tartari, Asuncion Lafuente, Carla Abdelnour, Montserrat Alegret, Sara Jofresa, Mar Buendia, Ana Pancho, Nuria Aguilera, Marta Ibarria, Susana Diego, Rosario Cuevas, Laia Canada, Anna Calvet, Ester Esteban-De Antonio, Alba Perez-Cordon, Angela Sanabria, Itziar de Rojas, Raul Nunez-Llaves, Amanda Cano, Adelina Orellana, Laura Montrreal, Pilar Canabate, Maitee Rosende-Roca, Liliana Vargas, Urszula Bojaryn, Mario Ricciardi, Diana M. Ariton, Ana Espinosa, Gemma Ortega, Nathalia Munoz, Nuria Lleonart, Emilio Alarcon-Martin, Mariola Moreno, Silvia Preckler, Natalia Tantinya, Maribel Ramis, Ana Belen Nogales, Susanna Seguer, Elvira Martin, Vanesa Pytel, Sergi Valero, Miren Gurruchaga, Lluis Tarraga, Agustin Ruiz, Merce Boada

Summary: The pathophysiological mechanisms of cognitive impairment in Alzheimer's disease involve neuroinflammation and oxidative stress. The standardized extract of Ginkgo biloba EGb 761 has been shown to interfere with these mechanisms. This study aims to compare changes in blood markers of inflammation and oxidative stress after treatment with EGb 761 in patients with mild cognitive impairment, and also assess changes in cognitive test scores.

SCIENTIFIC REPORTS (2023)

Article Biochemistry & Molecular Biology

A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer's disease exacerbated with high fat diet

Triana Espinosa-Jimenez, Amanda Cano, Elena Sanchez-Lopez, Jordi Olloquequi, Jaume Folch, Monica Bullo, Ester Verdaguer, Carme Auladell, Caterina Pont, Diego Munoz-Torrero, Antoni Parcerisas, Antoni Camins, Miren Ettcheto

Summary: This study evaluated the effects of a synthesized inhibitor called RHE-HUP on APP/PS1 mice, a familial AD mouse model challenged by high-fat diet to simulate a T2DM-like condition. Results showed that RHE-HUP reduced the main hallmarks of AD, including Tau hyperphosphorylation, A beta(42) peptide levels, and plaque formation. Additionally, it decreased inflammation, increased synaptic proteins and neurotrophic factors, leading to memory improvement. Importantly, these improvements were observed at a central level without peripheral modifications induced by HFD consumption.

CELL AND BIOSCIENCE (2023)

Article Biotechnology & Applied Microbiology

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

Amanda Cano, Ester Esteban-de-Antonio, Mireia Bernuz, Raquel Puerta, Pablo Garcia-Gonzalez, Itziar de Rojas, Claudia Olive, Alba Perez-Cordon, Laura Montrreal, Raul Nunez-Llaves, Oscar Sotolongo-Grau, Emilio Alarcon-Martin, Sergi Valero, Montserrat Alegret, Elvira Martin, Pamela V. Martino-Adami, Miren Ettcheto, Antonio Camins, Assumpta Vivas, Marta Gomez-Chiari, Miguel angel Tejero, Adelina Orellana, Lluis Tarraga, Marta Marquie, Alfredo Ramirez, Merce Marti, Maria Isabel Pividori, Merce Boada, Agustin Ruiz

Summary: Alzheimer's disease (AD) is commonly preceded by a prodromal phase characterized by high levels of A beta and p-tau-mediated neuronal injury and mild cognitive impairment (MCI). Differential diagnosis of MCI causes in these prodromal stages is a challenge for clinicians. Blood biomarkers, particularly plasma extracellular vesicles (pEVs), are emerging as potential tools for early AD detection.

JOURNAL OF NANOBIOTECHNOLOGY (2023)

Article Neurosciences

Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment: The NORFACE cohort

Marta Marquie, Ainhoa Garcia-Sanchez, Emilio Alarcon-Martin, Joan Martinez, Miguel Castilla-Marti, Luis Castilla-Marti, Adelina Orellana, Laura Montrreal, Itziar de Rojas, Pablo Garcia-Gonzalez, Raquel Puerta, Claudia Olive, Amanda Cano, Isabel Hernandez, Maitee Rosende-Roca, Liliana Vargas, Juan Pablo Tartari, Ester Esteban-De Antonio, Urszula Bojaryn, Mario Ricciardi, Diana M. Ariton, Vanesa Pytel, Montserrat Alegret, Gemma Ortega, Ana Espinosa, Alba Perez-Cordon, Angela Sanabria, Nathalia Munoz, Nuria Lleonart, Nuria Aguilera, Lluis Tarraga, Sergi Valero, Agustin Ruiz, Merce Boada

Summary: This study aimed to investigate the association between macular vessel density measured by optical coherence tomography angiography (OCT-A) and the AT(N) classification based on cerebrospinal fluid (CSF) biomarkers in individuals with mild cognitive impairment (MCI). The results showed that there was no association between macular vessel density measures and the AT(N) classification in MCI patients.

FRONTIERS IN NEUROSCIENCE (2023)

Review Biochemistry & Molecular Biology

Impact of New Drugs for Therapeutic Intervention in Alzheimer's Disease

Jordi Olloquequi, Miren Ettcheto, Amanda Cano, Elena Sanchez-Lopez, Marina Carrasco, Triana Espinosa, Carlos Beas-Zarate, Graciela Gudino-Cabrera, Monica E. Urena-Guerrero, Ester Verdaguer, Jaume Folch, Carme Auladell, Antoni Camins

Summary: The increasing population ageing and growth have led to a rise in the number of people living with dementia, with Alzheimer's disease being the most common cause. Although a cure for Alzheimer's disease has not been found yet, there are proposed treatments that may alter disease progression and help manage symptoms. In addition to the traditional hypotheses of Alzheimer's disease etiopathogenesis involving amyloid beta peptide accumulation and tau hyperphosphorylation, there is a trend that emphasizes the role of other molecular mechanisms, prompting the study of different therapeutic targets.

FRONTIERS IN BIOSCIENCE-LANDMARK (2022)

暂无数据